Implementation of DWM in Dutch SMEs
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorVU University of Amsterdam
About this trial
The goal of this cluster randomized controlled trial is to explore if mental health in Dutch small and medium-sized enterprises (SMEs) can be improved by the World Health Organization's online program Doing What Matters in Times of Stress (DWM). The main questions it aims to answer are:
* Does DWM improve the mental health of employees working in Dutch SMEs? * Does DWM improve work-related outcomes in employees working in Dutch SMEs? * How can DWM be implemented at a large scale in Dutch SMEs?
Researchers will compare two groups to see if the DWM program is effective. One group will receive the DWM program and Care-as-Usual (group 1), and the other group will receive Care-as-Usual only (group 2).
Participants will:
* Follow the online DWM program for 5 weeks (only group 1). * Take part in 6 telephone appointments with a facilitator (helper) that provides extra support to complete the program (only group 1). * Complete 3 sets of questionnaires. Each set of questionnaire takes about 15 minutes to be completed (group 1 and group 2).
Eligibility criteria
Qualifiers
Having 10 to 250 employees
Being located in the Netherlands
(In case of insufficient recruitment among SMEs, a mitigation strategy is to recruit individual departments from larger organizations)
18 years or older
Disqualifiers
Imminent suicide risk, or expressed acute needs or protection risks that require immediate follow-up
Currently receiving specialized psychological treatment (e.g., EMDR or CBT) at the time of screening
In case of current psychotropic medication use: being on an unstable dose for at least 2 months or a change in dosage over the past 2 months.
Having participated in the preceding ASCEND trial as supervisor (see NCT ID: NCT06989398)
Trial design
Treatments tested in this trial
- Doing What Matters in Times of Stress
Treatment groups
518 Participants
are divided into 2 treatment groupsSponsors and collaborators
VU University of Amsterdam
Lead sponsor
World Health Organization
Collaborator
University of Copenhagen
Collaborator
University Hospital Heidelberg
Collaborator
Source ClinicalTrials.gov